Relay Therapeutics, Inc.

Relay Therapeutics is a clinical-stage biotechnology company developing small molecule therapeutics for oncology and genetic diseases. The company employs computational biology and protein dynamics modeling to advance drug discovery, leveraging technology partnerships including collaboration with D. E. Shaw Research. Its pipeline includes RLY-2608, a phosphoinositide 3-kinase alpha inhibitor in clinical development for breast cancer and solid tumors, and programs targeting RAS family proteins, estrogen receptor degradation, and rare genetic conditions such as Fabry disease.

The company's revenue generation remains limited given its clinical-stage status. Current partnership arrangements include a collaboration with Pfizer for RLY-2608 combination studies and licensing agreements with Elevar Therapeutics for lirafugratinib development. As a clinical-stage entity, Relay does not generate product revenue, instead relying on partnership funding and capital raises to support research and development operations.

Relay maintains approximately 188 full-time employees and is headquartered in Cambridge, Massachusetts, with operations focused on the U.S. market. The company was incorporated in Delaware in 2015 and trades on the Nasdaq exchange.